

Roy W Beck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4882632/publications.pdf>

Version: 2024-02-01

169
papers

32,951
citations

5782

84
h-index

6024

165
g-index

170
all docs

170
docs citations

170
times ranked

15797
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 153-156.	2.4	10
2	Insulin Pump Infusion Set Failures Associated with Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 22,741 Infusion Set Wears. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 396-402.	2.4	16
3	Response to Comment on Aleppo et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> 2021;44:2729â€“2737. <i>Diabetes Care</i> , 2022, 45, e85-e86.	4.3	0
4	A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 573-582.	2.4	9
5	Continuous Glucose Monitoring Profiles in Healthy, Nondiabetic Young Children. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac060.	0.1	11
6	Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 324-331.	2.4	5
7	Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 299-306.	2.4	17
8	Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 593-599.	1.3	19
9	Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes Study. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 230-233.	2.4	5
10	More Time in Glucose Range During Exercise Days than Sedentary Days in Adults Living with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 376-383.	2.4	27
11	A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 367-375.	2.4	80
12	Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: <sc>MOBILE</sc> study baseline data. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 631-636.	2.2	9
13	A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. <i>Lancet, The</i> , 2021, 397, 208-219.	6.3	206
14	Predictors of Time-in-Range (70â€“180â€“mg/dL) Achieved Using a Closed-Loop Control System. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 475-481.	2.4	36
15	Beyond A1Câ€“Standardization of Continuous Glucose Monitoring Reporting: Why It Is Needed and How It Continues to Evolve. <i>Diabetes Spectrum</i> , 2021, 34, 102-108.	0.4	13
16	Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 401-409.	2.4	27
17	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2262.	3.8	182
18	An Evaluation of Two Capillary Sample Collection Kits for Laboratory Measurement of HbA1c. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 537-545.	2.4	31

#	ARTICLE	IF	CITATIONS
19	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> , 2021, 44, 2729-2737.	4.3	24
20	Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 473-478.	4.3	28
21	Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1330.	3.8	8
22	Diabetes Telehealth Solutions: Improving Self-Management Through Remote Initiation of Continuous Glucose Monitoring. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa076.	0.1	22
23	A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 836-845.	13.9	271
24	Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 1822-1828.	4.3	34
25	Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. <i>Endocrine Reviews</i> , 2020, 41, 756-774.	8.9	77
26	Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 501-508.	2.4	35
27	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2397.	3.8	191
28	Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2388.	3.8	238
29	Randomized Controlled Trial of Mobile Closed-Loop Control. <i>Diabetes Care</i> , 2020, 43, 607-615.	4.3	40
30	Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4356-4364.	1.8	118
31	Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1707-1717.	13.9	643
32	Advances in technology for management of type 1 diabetes. <i>Lancet, The</i> , 2019, 394, 1265-1273.	6.3	144
33	State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016â€“2018. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 66-72.	2.4	1,332
34	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019, 42, 1593-1603.	4.3	2,101
35	The T1D Exchange Clinic Network and Registry: 10 Years of Enlightenment on the State of Type 1 Diabetes in the United States. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 310-312.	2.4	13
36	Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data. <i>Diabetes Care</i> , 2019, 42, e60-e61.	4.3	17

#	ARTICLE	IF	CITATIONS
37	The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 1-5.	2.4	35
38	Response to Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. <i>Diabetes Care</i> 2018;41:2275-2280. <i>Diabetes Care</i> , 2019, 42, e29-e30.	4.3	3
39	The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 614-626.	1.3	286
40	Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. <i>Diabetes Care</i> , 2019, 42, 400-405.	4.3	508
41	Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 314-316.	2.4	180
42	Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry. <i>Hormone Research in Paediatrics</i> , 2018, 89, 47-55.	0.8	20
43	Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents. <i>Pediatric Diabetes</i> , 2018, 19, 420-428.	1.2	19
44	Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. <i>Lancet, The</i> , 2018, 392, 1321-1329.	6.3	302
45	Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2018, 41, 2275-2280.	4.3	396
46	Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. <i>Pediatric Diabetes</i> , 2018, 19, 1379-1384.	1.2	9
47	Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1909-1916.	4.3	59
48	Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 961-965.	1.2	35
49	Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. <i>Diabetes Care</i> , 2018, 41, 2155-2161.	4.3	184
50	Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network. <i>Diabetes</i> , 2018, 67, .	0.3	15
51	A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry. <i>Pediatric Diabetes</i> , 2017, 18, 222-229.	1.2	39
52	Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 359-366.	4.3	20
53	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 371.	3.8	834
54	REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 538-545.	4.3	230

#	ARTICLE	IF	CITATIONS
55	Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections. <i>Diabetes Therapy</i> , 2017, 8, 947-951.	1.2	47
56	Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2994-3001.	1.8	38
57	Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study. <i>Diabetes Care</i> , 2017, 40, 1002-1009.	4.3	122
58	Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A _{1c} Levels. <i>Annals of Internal Medicine</i> , 2017, 167, 95.	2.0	231
59	The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial. <i>Diabetes Care</i> , 2017, 40, 736-741.	4.3	205
60	Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 18-24.	2.4	120
61	Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. <i>Annals of Internal Medicine</i> , 2017, 167, 365.	2.0	385
62	The Fallacy of Average: How Using HbA _{1c} Alone to Assess Glycemic Control Can Be Misleading. <i>Diabetes Care</i> , 2017, 40, 994-999.	4.3	307
63	Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 700-708.	5.5	99
64	International Consensus on Use of Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2017, 40, 1631-1640.	4.3	1,376
65	Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension. <i>Pediatric Diabetes</i> , 2017, 18, 422-427.	1.2	10
66	Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. <i>Diabetes Care</i> , 2016, 39, 264-270.	4.3	86
67	Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. <i>Pediatric Diabetes</i> , 2016, 17, 266-273.	1.2	103
68	Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1216-1221.	1.3	31
69	Multinational Home Use of Closed-Loop Control Is Safe and Effective. <i>Diabetes Care</i> , 2016, 39, 1143-1150.	4.3	95
70	Effect of a Binocular iPad Game vs Part-time Patching in Children Aged 5 to 12 Years With Amblyopia. <i>JAMA Ophthalmology</i> , 2016, 134, 1391.	1.4	139
71	Design Considerations for Artificial Pancreas Pivotal Studies. <i>Diabetes Care</i> , 2016, 39, 1161-1167.	4.3	13
72	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 603-610.	4.3	126

#	ARTICLE	IF	CITATIONS
73	Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. <i>Diabetologia</i> , 2016, 59, 87-91.	2.9	203
74	Factors Associated with Nocturnal Hypoglycemia in At-Risk Adolescents and Young Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 385-391.	2.4	43
75	Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2015, 38, 971-978.	4.3	1,082
76	Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2137.	3.8	599
77	A Randomized Trial of Levodopa as Treatment for Residual Amblyopia in Older Children. <i>Ophthalmology</i> , 2015, 122, 874-881.	2.5	56
78	Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. <i>Pediatrics</i> , 2015, 135, 424-434.	1.0	282
79	A Web-Based Study of the Relationship of Duration of Insulin Pump Infusion Set Use and Fasting Blood Glucose Level in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 307-310.	2.4	16
80	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. <i>New England Journal of Medicine</i> , 2015, 372, 1193-1203.	13.9	1,255
81	Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis. <i>Diabetes Care</i> , 2015, 38, 1197-1204.	4.3	129
82	Evaluation of Stochastic Adjustment for Glucose Sensor Bias During Closed-Loop Insulin Delivery. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 186-192.	2.4	5
83	Frequency of Morning Ketosis After Overnight Insulin Suspension Using an Automated Nocturnal Predictive Low Glucose Suspend System. <i>Diabetes Care</i> , 2014, 37, 1224-1229.	4.3	42
84	A Randomized Trial Comparing Part-Time Patching with Observation for Children 3 to 10 Years of Age with Intermittent Exotropia. <i>Ophthalmology</i> , 2014, 121, 2299-2310.	2.5	54
85	A Novel Method to Detect Pressure-Induced Sensor Attenuations (PISA) in an Artificial Pancreas. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 1091-1096.	1.3	64
86	A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. <i>Pediatric Diabetes</i> , 2014, 15, 110-117.	1.2	102
87	A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 1885-1891.	4.3	141
88	Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2014, 37, 2702-2709.	4.3	278
89	Neuroanatomical Correlates of Dysglycemia in Young Children With Type 1 Diabetes. <i>Diabetes</i> , 2014, 63, 343-353.	0.3	110
90	Outpatient Safety Assessment of an In-Home Predictive Low-Glucose Suspend System with Type 1 Diabetes Subjects at Elevated Risk of Nocturnal Hypoglycemia. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 622-627.	2.4	89

#	ARTICLE	IF	CITATIONS
91	A Randomized Trial of Increasing Patching for Amblyopia. <i>Ophthalmology</i> , 2013, 120, 2270-2277.	2.5	59
92	The Effect of Donor Age on Penetrating Keratoplasty for Endothelial Disease. <i>Ophthalmology</i> , 2013, 120, 2419-2427.	2.5	85
93	Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3411-3419.	1.8	258
94	Exploratory Analysis of the Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2013, 131, 1033.	1.4	99
95	Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. <i>Pediatric Diabetes</i> , 2013, 14, 447-454.	1.2	209
96	Performance Comparison of the Medtronic Sof-Sensor and Enlite Glucose Sensors in Inpatient Studies of Individuals with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 758-761.	2.4	38
97	Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants. <i>Diabetes Care</i> , 2013, 36, 2009-2014.	4.3	415
98	The T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4383-4389.	1.8	392
99	Use of Continuous Glucose Monitoring as an Outcome Measure in Clinical Trials. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 877-882.	2.4	45
100	Impact of the Cornea Donor Study on Acceptance of Corneas From Older Donors. <i>Cornea</i> , 2012, 31, 1441-1445.	0.9	5
101	Evaluation of Visual Acuity Measurements After Autorefraction vs Manual Refraction in Eyes With and Without Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2012, 130, 470.	2.6	17
102	Optical Treatment of Strabismic and Combined Strabismic Anisometropic Amblyopia. <i>Ophthalmology</i> , 2012, 119, 150-158.	2.5	102
103	Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 351-358.	2.4	106
104	Visual Acuity Testing Using Autorefraction or Pinhole Occluder Compared with a Manual Protocol Refraction in Individuals with Diabetes. <i>Ophthalmology</i> , 2011, 118, 537-542.	2.5	25
105	The Burgeoning Public Health Impact of Diabetes. <i>JAMA Ophthalmology</i> , 2011, 129, 225.	2.6	7
106	RANDOMIZED TRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL PHOTOCOAGULATION. <i>Retina</i> , 2011, 31, 1009-1027.	1.0	126
107	Randomized Trial to Evaluate Combined Patching and Atropine for Residual Amblyopia. <i>JAMA Ophthalmology</i> , 2011, 129, 960-962.	2.6	34
108	The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitol, and continuous glucose monitoring. <i>Pediatric Diabetes</i> , 2011, 12, 690-695.	1.2	37

#	ARTICLE	IF	CITATIONS
109	Outcome Measures for Outpatient Hypoglycemia Prevention Studies. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 999-1004.	1.3	13
110	Hemoglobin A1c and Mean Glucose in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 540-544.	4.3	51
111	Persistence of Individual Variations in Glycated Hemoglobin. <i>Diabetes Care</i> , 2011, 34, 1315-1317.	4.3	61
112	Baseline Factors Related to Endothelial Cell Loss Following Penetrating Keratoplasty. <i>JAMA Ophthalmology</i> , 2011, 129, 1149.	2.6	42
113	Factors Predictive of Severe Hypoglycemia in Type 1 Diabetes: Analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. <i>Diabetes Care</i> , 2011, 34, 586-590.	4.3	59
114	Variation of Interstitial Glucose Measurements Assessed by Continuous Glucose Monitors in Healthy, Nondiabetic Individuals. <i>Diabetes Care</i> , 2010, 33, 1297-1299.	4.3	104
115	Pilot Study of Levodopa Dose as Treatment for Residual Amblyopia in Children Aged 8 Years to Younger Than 18 Years. <i>JAMA Ophthalmology</i> , 2010, 128, 1215.	2.6	41
116	A Randomized Trial Comparing Bangerter Filters and Patching for the Treatment of Moderate Amblyopia in Children. <i>Ophthalmology</i> , 2010, 117, 998-1004.e6.	2.5	118
117	A Proposed Method of Logarithmic Transformation of Optical Coherence Tomography Data for Use in Clinical Research. <i>Ophthalmology</i> , 2010, 117, 1512-1516.	2.5	29
118	Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. <i>Ophthalmology</i> , 2010, 117, 1064-1077.e35.	2.5	1,276
119	Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2047-2049.	4.3	114
120	To Mask or Not to Mask. <i>JAMA Ophthalmology</i> , 2009, 127, 801.	2.6	50
121	Observational Study of the Development of Diabetic Macular Edema Following Panretinal (Scatter) Photocoagulation Given in 1 or 4 Sitzings. <i>JAMA Ophthalmology</i> , 2009, 127, 132.	2.6	109
122	Effects of Dilation on Electronic-ETDRS Visual Acuity in Diabetic Patients. , 2009, 50, 1580.		6
123	The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1378-1383.	4.3	347
124	Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1954-1959.	4.3	53
125	Three-Year Follow-up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2009, 127, 245.	2.6	354
126	Comparison of the Amblyopia Treatment Study HOTV and the Electronic-Early Treatment of Diabetic Retinopathy Study visual acuity protocols in amblyopic children aged 5 to 11 years. <i>Journal of AAPOS</i> , 2009, 13, 75-78.	0.2	25

#	ARTICLE	IF	CITATIONS
127	Treatment of severe amblyopia with weekend atropine: Results from 2 randomized clinical trials. Journal of AAPOS, 2009, 13, 258-263.	0.2	93
128	Exploratory Analysis of Diabetic Retinopathy Progression Through 3 Years in a Randomized Clinical Trial That Compares Intravitreal Triamcinolone Acetonide With Focal/Grid Photocoagulation. JAMA Ophthalmology, 2009, 127, 1566.	2.6	79
129	Contrast Sensitivity Following Amblyopia Treatment in Children. JAMA Ophthalmology, 2009, 127, 1225.	2.6	24
130	Retinal Thickness on Stratus Optical Coherence Tomography in People with Diabetes and Minimal or No Diabetic Retinopathy. American Journal of Ophthalmology, 2008, 145, 894-901.e1.	1.7	98
131	A Randomized Trial of Atropine vs Patching for Treatment of Moderate Amblyopia. JAMA Ophthalmology, 2008, 126, 1039.	2.6	107
132	Patching vs Atropine to Treat Amblyopia in Children Aged 7 to 12 Years. JAMA Ophthalmology, 2008, 126, 1634.	2.6	150
133	Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal of Medicine, 2008, 359, 1464-1476.	13.9	1,369
134	Stability of Visual Acuity Improvement Following Discontinuation of Amblyopia Treatment in Children Aged 7 to 12 Years. JAMA Ophthalmology, 2007, 125, 655.	2.6	63
135	Comparison of the Modified Early Treatment Diabetic Retinopathy Study and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular Edema. JAMA Ophthalmology, 2007, 125, 469.	2.6	221
136	Relationship between Optical Coherence Tomographyâ€“Measured Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema. Ophthalmology, 2007, 114, 525-536.	2.5	520
137	A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema. Ophthalmology, 2007, 114, 1860-1867.e7.	2.5	438
138	Visual Acuity as an Outcome Measure in Clinical Trials of Retinal Diseases. Ophthalmology, 2007, 114, 1804-1809.	2.5	142
139	Treatment of Anisometropic Amblyopia in Children with Refractive Correction. Ophthalmology, 2006, 113, 895-903.	2.5	271
140	A Randomized Trial to Evaluate 2 Hours of Daily Patching for Strabismic and Anisometropic Amblyopia in Children. Ophthalmology, 2006, 113, 904-912.	2.5	191
141	Diurnal Variation in Retinal Thickening Measurement by Optical Coherence Tomography in Center-Involved Diabetic Macular Edema. JAMA Ophthalmology, 2006, 124, 1701.	2.6	69
142	Clinical Profile and Early Surgical Complications in the Cornea Donor Study. Cornea, 2006, 25, 164-170.	0.9	45
143	Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin. Diabetes Care, 2006, 29, 2200-2204.	4.3	194
144	Baseline Donor Characteristics in the Cornea Donor Study. Cornea, 2005, 24, 389-396.	0.9	70

#	ARTICLE	IF	CITATIONS
145	Randomized Trial of Treatment of Amblyopia in Children Aged 7 to 17 Years. <i>JAMA Ophthalmology</i> , 2005, 123, 437.	2.6	400
146	A Randomized Multicenter Trial Comparing the GlucoWatch Biographer With Standard Glucose Monitoring in Children With Type 1 Diabetes. <i>Diabetes Care</i> , 2005, 28, 1101-1106.	4.3	113
147	A Randomized Pilot Study of Near Activities Versus Non-Near Activities During Patching Therapy for Amblyopia. <i>Journal of AAPOS</i> , 2005, 9, 129-136.	0.2	76
148	Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus. <i>Journal of Pediatrics</i> , 2005, 147, 528-534.	0.9	238
149	Atropine Regimens for Amblyopia: Author reply. <i>Ophthalmology</i> , 2005, 112, 1481.	2.5	0
150	The Pediatric Eye Disease Investigator Group Report May Be Too Optimistic About Efficacy of Treatment: In Reply. <i>Pediatrics</i> , 2004, 114, 1366-1367.	1.0	0
151	A randomized trial of atropine regimens for treatment of moderate amblyopia in children. <i>Ophthalmology</i> , 2004, 111, 2076-2085.e4.	2.5	207
152	Recent Advances in the Treatment of Amblyopia. <i>Pediatrics</i> , 2004, 113, 1800-1802.	1.0	15
153	A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. <i>Ophthalmology</i> , 2003, 110, 2075-2087.	2.5	343
154	A computerized method of visual acuity testing. <i>American Journal of Ophthalmology</i> , 2003, 135, 194-205.	1.7	475
155	Reliability of the electronic early treatment diabetic retinopathy study testing protocol in children 7 to <13 years old. <i>American Journal of Ophthalmology</i> , 2003, 136, 655-661.	1.7	89
156	A Randomized Trial of Patching Regimens for Treatment of Moderate Amblyopia in Children. <i>JAMA Ophthalmology</i> , 2003, 121, 603.	2.6	407
157	Impact of Patching and Atropine Treatment on the Child and Family in the Amblyopia Treatment Study. <i>JAMA Ophthalmology</i> , 2003, 121, 1625.	2.6	142
158	Clinical research in pediatric ophthalmology: The Pediatric Eye Disease Investigator Group. <i>Current Opinion in Ophthalmology</i> , 2002, 13, 337-340.	1.3	32
159	Interferon γ -1a for early multiple sclerosis: CHAMPS trial subgroup analyses. <i>Annals of Neurology</i> , 2002, 51, 481-490.	2.8	130
160	Computerized method of visual acuity testing: adaptation of the amblyopia treatment study visual acuity testing protocol11Additional technical information about the Electronic Visual Acuity Tester and the Amblyopia Treatment Study visual acuity testing protocol application can be obtained from the lead author (pmoke@jaeb.org).. <i>American Journal of Ophthalmology</i> , 2001, 132, 903-909.	1.7	217
161	The amblyopia treatment index. <i>Journal of AAPOS</i> , 2001, 5, 250-254.	0.2	67
162	Predictors of nonrecovery in acute traumatic sixth nerve palsy and paresis11The authors have no financial interests in the products or devices mentioned herein.. <i>Ophthalmology</i> , 2001, 108, 1457-1460.	2.5	70

#	ARTICLE	IF	CITATIONS
163	The Analysis of Clinical Research: Mandatory Submission of Data Sets. JAMA Ophthalmology, 2000, 118, 275.	2.6	2
164	Botulinum toxin treatment versus conservative management in acute traumatic sixth nerve palsy or paresis. Journal of AAPOS, 2000, 4, 145-149.	0.2	72
165	Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis. New England Journal of Medicine, 2000, 343, 898-904.	13.9	1,450
166	Letter to the Editor. Cornea, 2000, 19, 412.	0.9	0
167	Is Donor Age an Important Determinant of Graft Survival?. Cornea, 1999, 18, 503-510.	0.9	53
168	The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis. New England Journal of Medicine, 1993, 329, 1764-1769.	13.9	563
169	A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. New England Journal of Medicine, 1992, 326, 581-588.	13.9	1,191